New Research Shows Gazelle Diagnostic Device Outperformed Rapid Diagnostic Test for P. Vivax Malaria, Detected Challenging Types of Malaria, and Provided Accurate Sickle Cell Disease Detection
November 15, 2020 14:00 ET
|
Hemex Health
PORTLAND, Ore., Nov. 15, 2020 (GLOBE NEWSWIRE) -- Hemex Health, an innovator in point-of-care diagnostic technologies, announced today that researchers will present five scientific posters at the...
Imara Reports Third Quarter 2020 Financial Results and Business Highlights
November 05, 2020 07:00 ET
|
Imara, Inc.
Patient Dosing Underway in Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia IMR-687 granted Orphan Drug designation from European Commission for sickle cell disease ...
$397.79 Millions Sickle Cell Anemia Testing and Screening Markets, 2027
October 29, 2020 07:53 ET
|
Research and Markets
Dublin, Oct. 29, 2020 (GLOBE NEWSWIRE) -- The "Sickle Cell Anemia Testing and Screening - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering. Global...
Imara to Webcast Conference Call of Third Quarter Financial Results
October 29, 2020 07:00 ET
|
Imara, Inc.
BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Global Hematology and Coagulation Testing Markets Report 2020 with Discussion of COVID-19
October 28, 2020 06:53 ET
|
Research and Markets
Dublin, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The "Hematology and Coagulation Markets (Lab-based and Decentralized Markets)" report has been added to ResearchAndMarkets.com's offering. Hematology and...
NIH Awards Prize to Hemex Health’s Non-Invasive Sickle Cell, Malaria, Anemia Rapid Test (“SMART”) Diagnostic Technology
October 26, 2020 08:00 ET
|
Hemex Health
PORTLAND, Ore., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Researchers from Hemex Health, Medtronic plc, Case Western Reserve University, and the University of Nebraska Medical Center’s International...
Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-Thalassemia
October 16, 2020 07:00 ET
|
Imara, Inc.
BOSTON, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Report [2020-2026] Sickle Cell Disease Treatment Market Size, Share, Growth, Trends, Analysis, Competitive Landscape, Forecast by Fortune Business Insights™
October 13, 2020 07:07 ET
|
Fortune Business Insights
Pune, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Increasing impetus to research on gene therapy to treat sickle cell disease is a key factor contributing to the global sickle cell disease treatment market,...
Imara to Present at Upcoming Investor Conferences
September 02, 2020 07:00 ET
|
Imara, Inc.
BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell Disease
August 25, 2020 07:00 ET
|
Imara, Inc.
BOSTON, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...